跳至主要内容
临床试验/JPRN-UMIN000001124
JPRN-UMIN000001124已完成未知

Clinical Assessment to Establish the Symptomatic Advantage of Rabeprazole: double-blind, randomized, placebo-controlled study in functional dyspepsia - CAESAR study

Office of CAESAR study0 个研究点目标入组 120 人开始时间: 2008年4月29日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Organic disease such as reflux esophagitis (> grade A) and erosive gastritis. 2. Patients with past history of gastrectomy 3. NSAIDs or low-dose aspirin -related dyspepsia 4. Patients with organic disease in the brain or with psychological disorders 5. Patients with alcoholics or with drug dependence 6. Severe endocrine disease including hyperthyroidism 7. Severe diseases in heart, liver and kidney. Severe infectious or hemotological diseases 8. Drug allegy for rabeprazole 9. expectant mother, mother with breast-feeding 10. other not applicable person recognized by a doctor

研究者

发起方
Office of CAESAR study

相似试验